NCT06672965 is a NA clinical trial of anti-stress supplement in Evaluations, Diagnostic Self, sponsored by Pharmanex.

Who is sponsoring NCT06672965?

NCT06672965 is sponsored by Pharmanex.

What drugs are being tested in NCT06672965?

Interventions in NCT06672965: anti-stress supplement, Placebo.

What condition does NCT06672965 study?

NCT06672965 studies Evaluations, Diagnostic Self.

Is NCT06672965 still recruiting?

NCT06672965 is currently completed. Last updated 4 November 2024.

Last reviewed 2024-11-04 · How we verify

NCT06672965

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate the Efficacy of Dietary Supplement to Alleviate Stress Versus Placebo in Subjects with Mild to Moderate Levels of Stress

Completed NA Last updated 4 November 2024

What this trial tests

NA trial testing anti-stress supplement in Evaluations, Diagnostic Self in 60 participants. Completed in 30 July 2023.

Timeline

19 June 2023

Primary endpoint
20 July 2023

30 July 2023

Quick facts

Lead sponsor	Pharmanex
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	60
Start date	19 June 2023
Primary completion	20 July 2023
Estimated completion	30 July 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

anti-stress supplement
Placebo

Conditions studied

Evaluations, Diagnostic Self — all drugs for Evaluations, Diagnostic Self →

Sponsor

Pharmanex

Who can join

Adults 40 to 45, any sex, with Evaluations, Diagnostic Self. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single centre, double blind, placebo-controlled clinical study design in healthy subjects to evaluate the efficacy of dietary supplement to alleviate stress in subjects with mild to moderate stress

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phytochemicals Targeting BDNF Signaling for Treating Neurological Disorders.
Singh AA, Katiyar S, Song M. · · 2025 · cited 12× · PMID 40149774 · DOI 10.3390/brainsci15030252

Verify or expand the search:

Other Pharmanex trials

Trials by the same sponsor.

NCT07380438 — A Clinical Study to Evaluate the Efficacy of a Nutritional Supplement to Improve Carotenoid Content as Measured by a Non · NA · completed
NCT06680219 — Evaluation of the the Efficacy of a Digestive Health Supplement in Healthy Subjects · NA · completed
NCT05971771 — Study to Assess Impact of Dietary Supplement on Sleep Health · NA · unknown
NCT05041205 — Functional Test for a Drink Powder Alone and Combined Use With a Cosmetic Apparatus · NA · completed
NCT04230824 — Chronic Study on Body Composition, Training, Performance, and Recovery · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06672965 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pharmanex
Last refreshed: 4 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06672965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing